Clinical trial · no report yet · Phase 3
NCT04210115
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
- NCT04210115 ↗
- Completed
- Merck Sharp & Dohme LLC
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 5 | |
| Podcasts | 4 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC); Gastroesophageal Junction Carcinoma (GEJC); Esophageal Adenocarcinoma (EAC)
- Interventions
- pembrolizumab; placebo; cisplatin; 5-FU; radiotherapy; leucovorin; levoleucovorin; oxaliplatin
- Arms
- Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy · Experimental
- Placebo+FP or FOLFOX Therapy+Radiotherapy · Placebo comparator
- Enrollment
- 703
- Primary outcomes
- Event-free Survival (EFS)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Feb 28, 2020
- Primary completion
- Jan 21, 2026
- Results posted
- No
- Registry record
- NCT04210115 · updated Jul 22, 2026
Publications
linked from the registry- Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021 Apr;17(10):1143-1153. doi: 10.2217/fon-2020-0969. Epub 2021 Feb 3. PubMed 33533655